A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis.

Trial Profile

A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic conjunctivitis; Allergic rhinitis; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 26 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01731249 ).
    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2012 Additional trial location (Sweden) identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top